세계의 바이오칩 시장 : 제품 및 서비스별, 유형별, 제조 기술별, 최종 사용자별, 지역별, 예측(-2030년)

The biochips market is expected to grow from USD 14.01 billion in 2025 to USD 21.36 billion by 2030, at a CAGR of 8.8%. This growth is driven by several key factors shaping the future of diagnostics, genomics, and personalized medicine.

A major driver of this growth is the increasing demand for precision diagnostics and personalized treatments, fueled by advancements in genomics and the growing focus on individualized healthcare. As the healthcare industry shifts toward more tailored treatment plans, the adoption of biochips for applications like genetic testing, disease detection, and drug development is rapidly expanding.

Additionally, the growing demand for faster and more efficient diagnostics is driving the need for high-throughput, point-of-care testing solutions. Biochips, particularly DNA chips and lab-on-a-chip systems, play a crucial role in meeting this demand by providing rapid, cost-effective, and scalable diagnostic solutions. The ongoing trend toward decentralization in healthcare, where diagnostic tests and treatments are moving from centralized laboratories to more accessible settings, further boosts the adoption of biochips.

Technological advancements, such as the integration of artificial intelligence for data analysis and the development of microfluidic platforms, are also accelerating market growth. These innovations enhance the accuracy, speed, and ease of use of biochip systems, expanding their applications across various sectors, from research to clinical diagnostics.

Overall, the combination of rising healthcare demands, technological innovations, and the increasing shift toward personalized and decentralized healthcare is driving robust growth in the biochips market.

By product & service, the software & services segment is projected to grow at the highest CAGR during the forecast period.

The software & services segment is expected to see the highest growth in the biochips market, driven by the increasing need for advanced data analysis, AI-driven insights, and cloud integration in biochip applications. As biochips generate large volumes of complex biological data, sophisticated software solutions are essential for processing, interpreting, and visualizing results. Additionally, the rise in personalized medicine and precision diagnostics requires bioinformatics services to handle and analyze genetic, proteomic, and genomic data. These trends, coupled with the growing adoption of cloud-based platforms for data sharing and remote diagnostics, are driving the rapid growth of software and services in the biochips market.

By end user, the biotechnology and pharmaceutical companies segment accounted for the largest market share in 2024.

In 2024, the veterinary clinics segment dominated the biochips market due to the critical role biochips play in drug discovery, genomic research, and personalized medicine. These companies use biochips for high-throughput screening, biomarker discovery, and genetic profiling, which are essential for developing new therapies and improving treatment precision. The need for faster, more accurate, and cost-effective diagnostics and research tools drives strong demand for biochips in these industries. Additionally, biochips enable pharmaceutical companies to streamline drug development processes, making them an indispensable technology in the biotech and pharmaceutical sectors.

The Asia Pacific region is expected to witness the highest growth during the forecast period.

The Asia Pacific is poised to experience the highest growth in the biochips market, driven by rapid advancements in healthcare infrastructure, increasing government investments in biotechnology, and a growing focus on personalized medicine. The region's expanding pharmaceutical and biotechnology industries are driving demand for biochips in drug development, diagnostics, and genomic research. Additionally, rising healthcare awareness, improved healthcare access, and a growing middle class in countries such as China and India are accelerating the adoption of advanced diagnostic technologies, including biochips. This combination of economic growth, technological advancements, and healthcare innovations is driving the region's rapid market expansion.

Breakdown of supply-side primary interviews:

• By Company Type: Tier 1 (45%), Tier 2 (20%), and Tier 3 (35%)
• By Designation: C-level Executives (35%), Directors (25%), and Other Designations (40%)
• By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and Middle East & Africa (5%)

Breakdown of demand-side primary interviews:

• By End User: Biotechnology and Pharmaceutical Companies (40%), Hospitals and Diagnostic Centers (25%), Academic & Research Institutes (20%), Contract Research Organizations (CROs) (10%), and Other End Users (5%)

By Designation: Laboratory Managers / Heads (47%), Clinical Diagnostics Managers (22%), Genomics / Research Scientists (15%), and Others (16%)

• By Region: North America (25%), Europe (24%), Asia Pacific (25%), Latin America (11%), and the Middle East & Africa (15%)

Research Coverage

The market study covers the biochips market in various segments. It aims to estimate the market size and growth potential of this market by products & services, type, fabrication technology, end user, and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their products and business offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report can assist established companies and newer or smaller firms in understanding market trends, enabling them to capture a larger market share. Firms that acquire the report can implement one or more of the five strategies outlined below.

This report provides insights into the following points:

• Analysis of key drivers (Growing demand for personalized medicines, Technological advancements in microfluidics and AI integration), restraints (High cost of biochip development and fabrication, Data management and standardization issues), opportunities (Expanding applications in point-of-care and decentralized diagnostics, Increasing government and private investments in genomics research), and challenges (Technical complexity and integration of multidisciplinary technologies, Regulatory and validation hurdles for clinical use) influencing the growth of the biochips market.
• Product Development/Innovation: Detailed insights on upcoming technologies and product launches in the biochips market.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of biochips across regions.
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the biochips market.
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the biochips market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
• 2.2 RESEARCH METHODOLOGY
  • 2.2.1 SECONDARY DATA
    • 2.2.1.1 Key data from secondary sources
  • 2.2.2 PRIMARY DATA
    • 2.2.2.1 Key data from primary sources
    • 2.2.2.2 Key industry insights
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 BOTTOM-UP APPROACH
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.5 MARKET SHARE ANALYSIS
  • 2.5.1 RESEARCH ASSUMPTIONS
  • 2.5.2 GROWTH RATE ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
  • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.6.2 SCOPE-RELATED LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 BIOCHIPS MARKET OVERVIEW
• 4.2 ASIA PACIFIC: BIOCHIPS MARKET, BY PRODUCTS & SERVICES & COUNTRY (2024)
• 4.3 BIOCHIPS MARKET: REGIONAL MIX
• 4.4 BIOCHIPS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.5 BIOCHIPS MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising adoption of personalized medicine
    • 5.2.1.2 Technological advancements in microarray and microfluidics fabrication
    • 5.2.1.3 Increasing R&D investments in genomics and proteomics
    • 5.2.1.4 Advancements in point-of-care diagnostics and lab-on-a-chip technologies
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of instruments and fabrication
    • 5.2.2.2 Complex data interpretation and standardization
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Integration of AI and bioinformatics in biochip data analysis
    • 5.2.3.2 Expansion into emerging markets and new applications
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Technical complexity and integration of multidisciplinary technologies
    • 5.2.4.2 Regulatory and validation hurdles for clinical use
• 5.3 INDUSTRY TRENDS
  • 5.3.1 MINIATURIZATION, PORTABILITY, AND DECENTRALIZED DIAGNOSTICS
  • 5.3.2 SHIFT TOWARD MICROFLUIDICS AND LAB-ON-A-CHIP FORMATS
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 Digital microfluidic biochips
    • 5.4.1.2 Plasmonic and nanoplasmonic biochips
    • 5.4.1.3 Wearable and implantable biochips
  • 5.4.2 ADJACENT TECHNOLOGIES
    • 5.4.2.1 AI/Machine learning for biochip data & design
    • 5.4.2.2 Optical genome mapping chips
  • 5.4.3 COMPLEMENTARY TECHNOLOGIES
    • 5.4.3.1 Advanced microfabrication and 3D printing
    • 5.4.3.2 Biochip integration in biosensors
• 5.5 PORTER'S FIVE FORCES ANALYSIS
  • 5.5.1 THREAT OF NEW ENTRANTS
  • 5.5.2 THREAT OF SUBSTITUTES
  • 5.5.3 BARGAINING POWER OF SUPPLIERS
  • 5.5.4 BARGAINING POWER OF BUYERS
  • 5.5.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.6 REGULATORY LANDSCAPE
  • 5.6.1 REGULATORY ANALYSIS
  • 5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.7 PATENT ANALYSIS
  • 5.7.1 PATENT PUBLICATION TRENDS FOR BIOCHIPS
  • 5.7.2 JURISDICTION AND TOP APPLICANT ANALYSIS
• 5.8 TRADE ANALYSIS
  • 5.8.1 IMPORT DATA FOR HS CODE 9027
  • 5.8.2 EXPORT DATA FOR HS CODE 9027
• 5.9 PRICING ANALYSIS
  • 5.9.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
  • 5.9.2 AVERAGE SELLING PRICE TREND, BY REGION
    • 5.9.2.1 Average selling price of DNA chips and lab-on-a-chip, by region
    • 5.9.2.2 Average selling price trend of DNA chips, by region
    • 5.9.2.3 Average selling price trend of lab-on-a-chip, by region
    • 5.9.2.4 Average selling price trend of protein chips, by region
• 5.10 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.11.2 BUYING CRITERIA
• 5.12 END-USER ANALYSIS AND UNMET NEEDS
• 5.13 IMPACT OF AI/GENERATIVE AI ON BIOCHIPS MARKET
  • 5.13.1 INTRODUCTION
  • 5.13.2 MARKET POTENTIAL IN BIOCHIPS ECOSYSTEM
  • 5.13.3 AI-USE CASES
  • 5.13.4 KEY COMPANIES IMPLEMENTING AI IN BIOCHIPS MARKET
• 5.14 ECOSYSTEM ANALYSIS
• 5.15 CASE STUDY ANALYSIS
  • 5.15.1 MICROFLUIDIC BIOCHIP-BASED MULTIPLEXED PROFILING FOR EARLY CANCER DETECTION
  • 5.15.2 POINT-OF-CARE TUMOR MARKER DETECTION BIOCHIP
  • 5.15.3 GRAPHENE QUANTUM DOT-BASED BIOCHIP FOR CHILDHOOD LEUKEMIA DETECTION
• 5.16 VALUE CHAIN ANALYSIS
• 5.17 SUPPLY CHAIN ANALYSIS
• 5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.19 INVESTMENT AND FUNDING SCENARIO
• 5.20 US TARIFF IMPACT ON BIOCHIPS MARKET
  • 5.20.1 INTRODUCTION
  • 5.20.2 KEY TARIFF RATES
  • 5.20.3 PRICE IMPACT ANALYSIS
  • 5.20.4 IMPACT ON COUNTRY/REGION
  • 5.20.5 IMPACT ON END-USE INDUSTRIES
    • 5.20.5.1 Biotechnology and pharmaceutical companies
    • 5.20.5.2 Hospitals and diagnostic centers
    • 5.20.5.3 Academic & research institutes
    • 5.20.5.4 Contract Research Organizations (CROs)
    • 5.20.5.5 Other end users

6 BIOCHIPS MARKET, BY PRODUCTS & SERVICES

• 6.1 INTRODUCTION
• 6.2 CONSUMABLES
  • 6.2.1 SURGE IN APPLICATIONS ACROSS PERSONALIZED MEDICINE AND PRECISION DIAGNOSTICS TO AID GROWTH
• 6.3 INSTRUMENTS
  • 6.3.1 RISING DEMAND FOR ADVANCED INSTRUMENTS TO ENHANCE PRECISION AND EFFICIENCY TO DRIVE MARKET
• 6.4 SOFTWARE & SERVICES
  • 6.4.1 INCREASING NEED FOR ADVANCED DATA ANALYSIS AND BIOINFORMATICS TO SUPPORT GROWTH

7 BIOCHIPS MARKET, BY TYPE

• 7.1 INTRODUCTION
• 7.2 DNA CHIPS
  • 7.2.1 GLOBAL VOLUME ANALYSIS OF DNA CHIPS, 2023-2030 (THOUSAND UNITS)
  • 7.2.2 DNA CHIPS MARKET, BY APPLICATION
    • 7.2.2.1 Gene expression
      • 7.2.2.1.1 Increasing cancer incidence and rising funding for genomic research to foster growth
    • 7.2.2.2 SNP genotyping
      • 7.2.2.2.1 Growing adoption of genetic screening programs and direct-to-consumer genomics services to fuel market
    • 7.2.2.3 Cancer diagnostics & treatment
      • 7.2.2.3.1 Rising global cancer burden and expanding reimbursement coverage to spur growth
    • 7.2.2.4 Genomics
      • 7.2.2.4.1 Rise of personalized medicine and increasing need for non-invasive diagnostics to facilitate growth
    • 7.2.2.5 Drug discovery
      • 7.2.2.5.1 Increasing application of DNA chips in drug discovery to identify targets and optimize therapeutics to boost market
    • 7.2.2.6 Agricultural biotechnology
      • 7.2.2.6.1 Growing use of DNA chips for crop improvement and trait analysis to propel market
    • 7.2.2.7 Other DNA chip applications
• 7.3 LAB-ON-A-CHIP
  • 7.3.1 GLOBAL VOLUME ANALYSIS OF LAB-ON-A-CHIP, 2023-2030 (THOUSAND UNITS)
  • 7.3.2 LAB-ON-A-CHIP MARKET, BY APPLICATION
    • 7.3.2.1 Clinical diagnostics
      • 7.3.2.1.1 Rising burden of chronic and infectious diseases to accelerate growth
    • 7.3.2.2 Genomics
      • 7.3.2.2.1 Increasing proliferation of genomic testing programs to stimulate growth
    • 7.3.2.3 IVD & POC
      • 7.3.2.3.1 Growing emphasis on early disease detection, chronic disease monitoring, and home-based testing to fuel market
    • 7.3.2.4 Proteomics
      • 7.3.2.4.1 Rise in biologic and biosimilar development to contribute to growth
    • 7.3.2.5 Drug discovery
      • 7.3.2.5.1 Increasing demand for high-throughput screening to augment growth
    • 7.3.2.6 Other LOAC applications
• 7.4 PROTEIN CHIPS
  • 7.4.1 GLOBAL VOLUME ANALYSIS OF PROTEIN CHIPS, 2023-2030 (THOUSAND UNITS)
  • 7.4.2 PROTEIN CHIPS MARKET, BY APPLICATION
    • 7.4.2.1 Proteomics
      • 7.4.2.1.1 Increasing focus on large-scale protein profiling to aid growth
    • 7.4.2.2 Expression profiling
      • 7.4.2.2.1 Surge in demand for systems-level understanding of cellular processes to support growth
    • 7.4.2.3 Diagnostics
      • 7.4.2.3.1 Increasing integration of protein-chip technology into clinical diagnostic workflows to encourage growth
    • 7.4.2.4 High-throughput screening
      • 7.4.2.4.1 Rising demand for rapid target validation and growing complexity of biologic therapeutics to drive market
    • 7.4.2.5 Drug discovery
      • 7.4.2.5.1 Need for efficient target identification and screening to favor growth
    • 7.4.2.6 Other protein chip applications
• 7.5 TISSUE ARRAYS
  • 7.5.1 INCREASING DEMAND FOR LARGE-SCALE VALIDATION OF BIOMARKERS TO SPUR GROWTH
  • 7.5.2 GLOBAL VOLUME ANALYSIS OF TISSUE ARRAYS, 2023-2030 (THOUSAND UNITS)
• 7.6 CELL ARRAYS
  • 7.6.1 EXPANDING USE OF CELL ARRAYS FOR HIGH-THROUGHPUT CELLULAR ANALYSIS AND DRUG SCREENING TO AID GROWTH
  • 7.6.2 GLOBAL VOLUME ANALYSIS OF CELL ARRAYS, 2023-2030 (THOUSAND UNITS)

8 BIOCHIPS MARKET, BY FABRICATION TECHNOLOGY

• 8.1 INTRODUCTION
• 8.2 MICROARRAYS
  • 8.2.1 WIDESPREAD ADOPTION OF MICROARRAYS IN GENOMIC AND PROTEOMIC RESEARCH TO FUEL MARKET
• 8.3 MICROFLUIDICS
  • 8.3.1 GROWING DEMAND FOR DECENTRALIZED, POINT-OF-CARE DIAGNOSTICS, AND HIGH-THROUGHPUT SCREENING TOOLS TO DRIVE MARKET

9 BIOCHIPS MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES
  • 9.2.1 RISING TREND OF PERSONALIZED AND PRECISION THERAPEUTICS TO EXPEDITE GROWTH
• 9.3 HOSPITALS & DIAGNOSTIC CENTERS
  • 9.3.1 INCREASING HOSPITAL INVESTMENTS IN MOLECULAR PATHOLOGY TO EXPEDITE GROWTH
• 9.4 ACADEMIC & RESEARCH INSTITUTES
  • 9.4.1 GROWING USE OF BIOCHIPS IN GENE-FUNCTION RELATIONSHIPS, PROTEIN NETWORKS, AND DISEASE MECHANISMS TO BOOST MARKET
• 9.5 CONTRACT RESEARCH ORGANIZATIONS (CROS)
  • 9.5.1 INCREASING TREND OF OUTSOURCING RESEARCH AND DEVELOPMENT ACTIVITIES TO PROMOTE GROWTH
• 9.6 OTHER END USERS

10 BIOCHIPS MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 NORTH AMERICA: VOLUME ANALYSIS, BY TYPE, 2023-2030 (THOUSAND UNITS)
  • 10.2.3 US
    • 10.2.3.1 Presence of prominent companies and high cancer prevalence to expedite growth
  • 10.2.4 CANADA
    • 10.2.4.1 Expanding genomics and precision medicine initiatives to drive market
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 EUROPE: VOLUME ANALYSIS, BY TYPE, 2023-2030 (THOUSAND UNITS)
  • 10.3.3 GERMANY
    • 10.3.3.1 Robust ecosystem of biotech startups and multinational corporations to promote growth
  • 10.3.4 UK
    • 10.3.4.1 Increasing healthcare investments and genomic advancements to drive market
  • 10.3.5 FRANCE
    • 10.3.5.1 Strong government initiatives in biotechnology, precision medicine, and healthcare innovations to boost market
  • 10.3.6 ITALY
    • 10.3.6.1 Growing demand for precision medicine to spur growth
  • 10.3.7 SPAIN
    • 10.3.7.1 Increasing demand for personalized medicine and strong governmental & institutional support to propel market
  • 10.3.8 NETHERLANDS
    • 10.3.8.1 Increasing emphasis on genomics and personalized medicine to favor growth
  • 10.3.9 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 ASIA PACIFIC: VOLUME ANALYSIS, BY TYPE, 2023-2030 (THOUSAND UNITS)
  • 10.4.3 CHINA
    • 10.4.3.1 Rising healthcare demand to support growth
  • 10.4.4 JAPAN
    • 10.4.4.1 Increasing geriatric population to drive market
  • 10.4.5 INDIA
    • 10.4.5.1 Strong government support for domestic biotech manufacturing to facilitate growth
  • 10.4.6 AUSTRALIA
    • 10.4.6.1 Increasing advancements in biotechnology to spur growth
  • 10.4.7 SOUTH KOREA
    • 10.4.7.1 Increasing healthcare expenditure to expedite growth
  • 10.4.8 THAILAND
    • 10.4.8.1 Rising healthcare investments to accelerate growth
  • 10.4.9 NEW ZEALAND
    • 10.4.9.1 Increasing focus on early detection and improving survival rates to drive market
  • 10.4.10 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 10.5.2 LATIN AMERICA: VOLUME ANALYSIS, BY TYPE, 2023-2030 (THOUSAND UNITS)
  • 10.5.3 BRAZIL
    • 10.5.3.1 Increasing demand for precision medicine and advancements in genomics to foster growth
  • 10.5.4 MEXICO
    • 10.5.4.1 Rising prevalence of chronic and infectious conditions to contribute to growth
  • 10.5.5 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 10.6.2 MIDDLE EAST & AFRICA: VOLUME ANALYSIS, BY TYPE, 2023-2030 (THOUSAND UNITS)
  • 10.6.3 GCC COUNTRIES
    • 10.6.3.1 Kingdom of Saudi Arabia (KSA)
      • 10.6.3.1.1 Strong public healthcare funding and rapid expansion of hospital infrastructure to aid growth
    • 10.6.3.2 United Arab Emirates (UAE)
      • 10.6.3.2.1 Growing integration of advanced diagnostic technologies to fuel market
    • 10.6.3.3 Rest of GCC Countries
  • 10.6.4 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
• 11.3 REVENUE SHARE ANALYSIS, 2020-2024
• 11.4 MARKET SHARE ANALYSIS, 2024
  • 11.4.1 GLOBAL MARKET SHARE ANALYSIS, 2024
  • 11.4.2 US MARKET SHARE ANALYSIS, 2024
• 11.5 COMPANY VALUATION AND FINANCIAL METRICS
  • 11.5.1 COMPANY VALUATION
  • 11.5.2 FINANCIAL METRICS
• 11.6 BRAND/PRODUCT COMPARATIVE ANALYSIS
• 11.7 R&D EXPENDITURE OF KEY PLAYERS
• 11.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 11.8.1 STARS
  • 11.8.2 EMERGING LEADERS
  • 11.8.3 PERVASIVE PLAYERS
  • 11.8.4 PARTICIPANTS
  • 11.8.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 11.8.5.1 Company footprint
    • 11.8.5.2 Region footprint
    • 11.8.5.3 Product & service footprint
    • 11.8.5.4 Type footprint
    • 11.8.5.5 Fabrication technology footprint
• 11.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 11.9.1 PROGRESSIVE COMPANIES
  • 11.9.2 RESPONSIVE COMPANIES
  • 11.9.3 DYNAMIC COMPANIES
  • 11.9.4 STARTING BLOCKS
  • 11.9.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 11.9.5.1 Detailed list of key startups/SMEs
    • 11.9.5.2 Competitive benchmarking of key startups/SMEs
• 11.10 COMPETITIVE SCENARIO
  • 11.10.1 PRODUCT/SERVICE LAUNCHES, ENHANCEMENTS, AND APPROVALS
  • 11.10.2 DEALS
  • 11.10.3 EXPANSIONS
  • 11.10.4 OTHER DEVELOPMENTS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 THERMO FISHER SCIENTIFIC INC.
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products/Services offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Product/Service launches, enhancements, and approvals
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Key strengths
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses and competitive threats
  • 12.1.2 ILLUMINA, INC.
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products/Services offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Product/Service launches, enhancements, and approvals
      • 12.1.2.3.2 Deals
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Key strengths
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses and competitive threats
  • 12.1.3 AGILENT TECHNOLOGIES, INC.
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products/Services offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Deals
      • 12.1.3.3.2 Expansions
      • 12.1.3.3.3 Other developments
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Key strengths
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses and competitive threats
  • 12.1.4 F. HOFFMANN-LA ROCHE LTD
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products/Services offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Product/Service launches, enhancements, and approvals
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Key strengths
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses and competitive threats
  • 12.1.5 QIAGEN
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products/Services offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Product/Service launches, enhancements, and approvals
      • 12.1.5.3.2 Deals
      • 12.1.5.3.3 Expansions
      • 12.1.5.3.4 Other developments
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Key strengths
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses and competitive threats
  • 12.1.6 BIO-RAD LABORATORIES, INC.
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products/Services offered
  • 12.1.7 ABBOTT
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products/Services offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Product/Service launches, enhancements, and approvals
  • 12.1.8 STANDARD BIOTOOLS
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products/Services offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Product/Service launches, enhancements, and approvals
      • 12.1.8.3.2 Deals
      • 12.1.8.3.3 Other developments
  • 12.1.9 10X GENOMICS
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products/Services offered
    • 12.1.9.3 Recent developments
      • 12.1.9.3.1 Product/Service launches, enhancements, and approvals
      • 12.1.9.3.2 Deals
      • 12.1.9.3.3 Other developments
  • 12.1.10 CEPHEID
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products/Services offered
    • 12.1.10.3 Recent developments
      • 12.1.10.3.1 Product/Service launches, enhancements, and approvals
      • 12.1.10.3.2 Deals
      • 12.1.10.3.3 Other developments
  • 12.1.11 BIOMERIEUX
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products/Services offered
      • 12.1.11.2.1 Product/Service launches, enhancements, and approvals
      • 12.1.11.2.2 Deals
  • 12.1.12 REVVITY
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products/Services offered
    • 12.1.12.3 Recent developments
      • 12.1.12.3.1 Deals
  • 12.1.13 DIASORIN S.P.A.
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products/Services offered
  • 12.1.14 RANDOX LABORATORIES LTD.
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products/Services offered
    • 12.1.14.3 Recent developments
      • 12.1.14.3.1 Product/Service launches, enhancements, and approvals
      • 12.1.14.3.2 Deals
      • 12.1.14.3.3 Expansions
  • 12.1.15 OXFORD GENE TECHNOLOGY IP LIMITED
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products/Services offered
• 12.2 OTHER PLAYERS
  • 12.2.1 MICRONIT B.V.
  • 12.2.2 RAYBIOTECH, INC.
  • 12.2.3 PHALANX BIOTECH GROUP
  • 12.2.4 ARRAYIT CORPORATION
  • 12.2.5 3DHISTECH LTD.
  • 12.2.6 CREATIVE BIOARRAY
  • 12.2.7 TISSUEARRAY.COM
  • 12.2.8 IBIOCHIPS
  • 12.2.9 CAPITALBIOTECH CO., LTD.
  • 12.2.10 PEPPERPRINT GMBH

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
  • 13.3.1 PRODUCT ANALYSIS
  • 13.3.2 COMPANY INFORMATION
  • 13.3.3 GEOGRAPHIC ANALYSIS
  • 13.3.4 REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS
  • 13.3.5 COUNTRY-LEVEL VOLUME ANALYSIS BY PRODUCT
  • 13.3.6 BY PRODUCT MARKET SHARE ANALYSIS (TOP 5 PLAYERS)
  • 13.3.7 ANY CONSULT/CUSTOM REQUIREMENTS AS PER CLIENT REQUESTS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS